A distinct set of CNS diseases are caused by autoantibodies to neuroglial surface proteins, and immunotherapy has limited ability to control these conditions in the long term. In this Review, the authors discuss in detail the B cell biology that underlies these diseases and consider the therapeutic implications.
- Bo Sun
- Melanie Ramberger
- Sarosh R. Irani